227 related articles for article (PubMed ID: 37754495)
21. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
da Veiga CRP; da Veiga CP; Drummond-Lage AP
Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
[TBL] [Abstract][Full Text] [Related]
22. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
23. Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study.
Garrido-Alejos G; Saborit-Canals G; Guarga L; de Pando T; Umbria M; Oriol A; Feliu A; Pontes C; Vallano A
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001598
[TBL] [Abstract][Full Text] [Related]
24. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
25. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
26. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Chan KKW
JAMA Oncol; 2022 Apr; 8(4):597-606. PubMed ID: 35201264
[TBL] [Abstract][Full Text] [Related]
29. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
30. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach.
Tingstedt B; Andersson E; Flink A; Bolin K; Lindgren B; Andersson R
World J Surg; 2011 Oct; 35(10):2298-305. PubMed ID: 21850604
[TBL] [Abstract][Full Text] [Related]
33. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
34. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
36. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
37. The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017-2019.
Seweryn M; Banas T; Augustynska J; Lorenc O; Kopel J; Pluta E; Skora T
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554267
[TBL] [Abstract][Full Text] [Related]
38. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
39. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
40. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
